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Abstract. Mesenchymal stromal cells (MSCs) possess 
self-renewal and multilineage differentiation potential, 
indicating their prospects as cellular therapeutic agents for 
regenerative medicine. Although adult bone marrow (BM) 
is the major source of these cells for clinical use, harvesting 
requires invasive procedures. Therefore, alternative sources, 
such as peripheral blood (PB), are needed. The objec-
tive of the current study was to compare PB-MSCs and 
BM-MSCs with regard to their biological characteristics. 
PB-MSCs and BM-MSCs were isolated from 4-week-old 
BALB/c white mice by density gradient centrifugation 
and cultured in DMEM + 10% fetal bovine serum until 
passage four. Morphological features, proliferation, cell 
surface marker expression and trilineage differentiation 
potential were assessed for both PB-MSCs and BM-MSCs. 
No significant differences in morphological features were 
observed. BM-MSCs had a higher proliferative capability 
than PB-MSCs as measured by XTT assays. Both PB-MSCs 
and BM-MSCs had broadly similar cell surface marker 
expression, but PB-MSCs had positive expression of cluster 
of differentiation (CD)146 and CD140b. Both PB-MSCs 
and BM-MSCs were capable of trilineage differentiation. 
Although BM-MSCs had a greater capacity for osteogenic 
and chondrogenic differentiation than PB-MSCs, PB-MSCs 
had a better capability for adipogenic differentiation than 
BM-MSCs. In conclusion, PB-MSCs and BM-MSCs have 
very similar biological characteristics. Thus, PB is a prom-
ising source for easily obtaining MSCs in mice.
Introduction
Mesenchymal stem cells (MSCs) are adult stem cells that 
have a promising role in regenerative medicine (1). MSCs 
are multipotent and self-renewing cells and can differentiate 
into several types of cells (2). These cells are suitable for use 
in clinical applications because of their various properties, 
such as low immunogenicity, immunomodulatory effects (3), 
migration potential to sites of injury (4) and regenerative 
potential (5). MSCs can be isolated from different sources, 
such as bone marrow (6), adipose tissue (7), umbilical cord (8), 
and dental pulp (9).
MSCs were first isolated from bone marrow (10). 
Then, research focused on the identification of a less 
invasive source of MSCs than bone marrow. Harvesting 
adipose-derived stem cells (ASCs) is less invasive than 
harvesting bone marrow stem cells (BM-SCs) and can be 
performed during liposuction and preferably in cases of 
autologous therapy (11,12). However, ASCs face further 
obstacles in the isolation steps, as they require digestion of 
adipose tissue using collagenase (7), which may affect cell 
viability. Therefore, identification of an alternative nonin-
vasive source that is suitable for autologous therapy and 
requires minimal manipulation is needed.
Recently, MSCs have been successfully isolated from 
the peripheral blood of rats, rabbits, canines, ovines and 
equines (13-19). The major problem with this source is 
the low levels of stem cells among mononuclear cells. 
Researchers tried to increase the number of stem cells in 
peripheral blood by injection of mobilizing agents, such 
granulocyte colony-stimulating factor (20). The present study 
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hypothesized that MSCs are found in peripheral blood at a 
certain percentage in mice and this percentage is inversely 
proportionate to age; its peak should be in the first weeks 
after birth.
In this study peripheral blood MSCs (PB-MSCs), were 
isolated from 4-week-old BALB/c white mice without using 
prior mobilizing agents and compared them with bone marrow 
MSCs (BM-MSCs).
Materials and methods
Ethical approval. The experimental protocol was approved 
by the Local Ethical Committee of the Faculty of Medicine, 
Mansoura University (Mansoura, Egypt) R/16.12.24.
Isolation of MSCs from BM and PB. MSCs were isolated 
from 4-week-old male BALB/c mice (weight, 15-20 g). A total 
of 6 mice were provided by Medical Experimental research 
Centre at the Faculty of Medicine, Mansoura University. 
Animals were housed in plastic cages (3/cage) on sawdust, 
with free access to food and water and were kept at a constant 
temperature of 22±1˚C with 50% relative humidity and 
12-h light/dark cycles for ≥1 week before the experiment. 
BM was isolated from mouse femurs and tibiae as previ-
ously described (21). PB was isolated from the same mouse 
by cardiac puncture as previously described (22). In both 
samples, mononuclear cells were isolated by density gradient 
centrifugation (400 x g; 30 min; 20˚C) and cultured in DMEM 
supplemented with 10% FBS and 1% antibiotic-antimycotic 
solution (all Thermo Fisher Scientific, Inc.) in 25 cm2 flasks. 
Flasks were incubated at 37˚C with 5% CO2 and the cells were 
cultured until passage 4.
XTT cell proliferation assay. In the XTT assay, passage 4 MSC 
proliferation was indirectly assessed by measuring metaboli-
cally active cells (23). MSCs were seeded at 125, 250, 500 and 
1,000 cells/well and allowed to grow for 7 days at different 
concentrations. Optical density was measured at 450 nm after 
the addition of the XTT reagent (Roche Diagnostics). The 
assay was repeated three times.
Flow cytometric analysis. Passage 4 MSCs were character-
ized using cell surface markers by fluorescence‑activated cell 
sorting analyses. The cells were stained with fluorescently 
labelled monoclonal antibodies against CD29, CD44, CD105, 
CD90.2, CD146, Sca-1, CD45 and CD140b (1 µg/ml; Miltenyi 
Biotec, Inc.; Table I) for 10 min in the dark at 2‑8˚C. All data 
were acquired using a flow cytometer and assessed using 
FACSDiva v8.0.1 (BD Biosciences).
Differentiation capability
Osteogenic differentiation. Passage 4 MSCs were harvested, 
counted and seeded at a density of 5x104 per well in a 6-well plate 
in osteogenesis differentiation media (DMEM supplemented 
with 10% FBS, 0.1 µM dexamethasone, 100 µM ascorbic 
acid and 10 mM β-glycerol phosphate from Sigma-Aldrich, 
Merck KGaA). The medium was changed twice per week for 
2-3 weeks. The differentiation potential for osteogenesis was 
assessed by 40 mM Alizarin Red (pH 4.1) for 15 min at room 
temperature after fixation in 10% neutral buffered formalin 
for 10 min at room temperature. Quantification of calcium 
deposition was performed with a commercial calcium assay 
kit (Sigma-Aldrich, Merck KGaA). The assay was repeated 
three times.
Adipogenic differentiation. Passage 4 MSCs were harvested, 
counted and seeded at a density of 5x104 per well in a 
24-well plate in adipogenesis differentiation media (DMEM 
supplemented with 10% FBS, 10% HS, 0.5 mM isobutylmeth-
ylxanthine, 60 mM indomethacin and 0.5 mM hydrocortisone 
from Sigma-Aldrich, Merck KGaA); the medium was changed 
twice per week for 2 weeks. The differentiation potential for 
adipogenesis and formation of intracellular lipid droplets were 
assessed by Oil red O for 15 min at room temperature after 
fixation in 10% neutral buffered formalin for 10 min at room 
temperature using semi quantitative scoring as described by 
Aldridge et al (24). The level of adipogenesis was evaluated by 
ranking 500 cells in the wells by their fat content. Ranks were 
divided on the basis of the fat proportion: Grade 1, 0-24%; 
grade 2, 25-49%; grade 3, 50-74%; grade 4, 75-100%. The 
assay was repeated three times.
Chondrogenic dif ferentiation. Passage 4 MSCs were 
harvested, counted and seeded at a density of 0.25x106 per 
Eppendorf tube in chondrogenic differentiation media 
[high-glucose DMEM supplemented with 10 ng/ml TGF-β3, 
100 nM dexamethasone, 200 µM ascorbate-2-phosphate, 
40 µg/ml proline, 1 mM pyruvate, 1 mg/ml bovine serum 
albumin (Sigma-Aldrich, Merck KGaA) and 50 mg/ml 
ITS +3]. The medium was replaced every 2-3 days for 21 days. 
Cell pellets were fixed in 10% formalin for 1 day at room 
temperature and embedded in paraffin wax at 58˚C for 
15 min. Sections of the cell pellets (5 µm) were stained with 
toluidine blue for 30 min at 37˚C (1% in 50% isopropanol) 
to demonstrate collagen content and sulfated proteogly-
cans within the extracellular matrix, indicated by blue 
color. Furthermore the production of sulfated GAG was 
measured in an Alcian blue binding assay (cat. no. 74240; 
Immunodiagnostic Systems) following digestion in 100 µl 
papain solution. Absorbance was read at 630 nm. The assay 
was repeated three times.
Statistical analysis. Data were presented as the mean ± stan-
dard deviation. Statistical differences between groups were 
analyzed by one-way analysis of variance followed by Tukey's 
post hoc test with a Stata 7.0 software package (StataCorp 
LLC.). All assays were repeated three times. P<0.05 was 
considered to indicate a statistically significant difference.
Results
XTT assay. BM‑MSCs showed a significantly greater optical 
density in XTT assays compared with PB-MSCs (P<0.05) 
and the difference increased as the cell number increased, 
indicating that BM-MSCs have a higher proliferative rate than 
PB-MSCs (Fig. 1).
Flow cytometric analysis. Cultures of passage 4 BM-MSCs 
and PB-MSCs were analyzed for the expression of cell-surface 
markers (Fig. 2). BM-MSCs were positive for CD29 and 
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negative for all other markers. PB-MSCs were positive for 
CD146, CD29 and CD140b and negative for Sca-1, CD44, 
CD45, CD90 and CD105.
Differentiation capability
Osteogenic differentiation. BM-MSCs and PB-MSCs differ-
entiated into osteoblasts (Fig. 3A and B). BM-MSCs appeared 
to have a greater capability to differentiate into osteoblasts 
than PB‑MSCs. Quantification of calcium deposition showed 
2.12±0.106 µg/ml differentiated BM-MSC osteoblasts 
and 1.91±0.6 µg/ml differentiated PB-MSC osteoblasts 
(Fig. 4A).
Adipogenic differentiation. BM-MSC and PB-MSC differ-
entiated into adipocyte (Fig. 3C and D) and PB-MSC 
exhibited a higher propensity to differentiate into adipocytes 
(Fig. 4B).
Chondrogenic differentiation. BM-MSCs and PB-MSCs 
tended to differentiate into chondrocytes (Fig. 3E and F), 
but BM-MSCs showed stronger production of sulfated GAG 
compared with PB-MSCs. The concentration of sulfated 
GAG in differentiated BM-MSCs was 17.93±2.44 µg/ml. The 
concentration of sulfated GAG in differentiated PB-MSCs was 
9.66±1.02 µg/ml (Fig. 4C).
Discussion
Bone marrow is the first and most common source of MSCs, 
but because collection of bone marrow is highly invasive, scien-
tists have tried to find an alternative source, such as adipose 
tissue. Although adipose tissue is a less invasive source than 
bone marrow, there are still problems in its processing and 
digestion. PB is also an easy source of MSCs. In this study, the 
biological characteristics of mouse PB-MSCs and BM-MSCs 
were compared with regard to the proliferation rate, surface 
markers and trilineage differentiation potential (osteogenic, 
adipogenic and chondrogenic).
The XTT assay showed that the proliferation rate of 
BM-MSCs was compared with the PB-MSCs when cells 
were cultured in a gradual concentration and were left for a 
week, which is consistent with Fu et al (16), who compared 
BM-MSCs and PB-MSCs in rats. Immunophenotypic charac-
terization also showed some differences, including CD146- and 
CD140b-positive expression only in PB-MSCs. CD146 expres-
sion in the MSC population showed heterogeneity in general 
and Espagnolle et al (25) demonstrated that MSCs with low 
CD146 expression had higher proliferation rates than MSCs 
with high CD146, which is consistent with the present study 
because PB-MSCs have high CD146 and low proliferation 
rates compared with BM-MSCs.
Both PB-MSCs and BM-MSCs could differentiate into 
osteoblasts, adipocytes and chondrocytes after these cells 
were cultured in differentiation-induction media compared 
with the control media. BM-MSCs showed higher differ-
entiation potential to osteoblasts and chondrocytes than 
PB-MSCs based on their calcium and GAG accumulation, 
which is consistent with the findings of Lyahyai et al (26) 
and Spaas et al (27). In contrast to Chong et al (28), 
PB-MSCs showed higher adipogenic differentiation than 
BM-MSCs as assessed by fat droplet formation. MSC circu-
lation in the bloodstream has been reported, but the exact 
tissue origin is debated. One theory states that PB-MSCs 
migrate from bone marrow, but the present study does not 
support this hypothesis because there are some biological 
differences (13,29).
Table I. Flow cytometry antibody panel used for characterization.
Name Conjugate Clone Cat. no. Supplier
CD29 PE HMs1-1 130-102-994 Miltenyi Biotec, Inc.
CD44 FITC IM7.8.1 130-102-511 Miltenyi Biotec, Inc.
CD105 PE MJ7/18 130-102-548 Miltenyi Biotec, Inc.
CD90.2 FITC 30-H12 130-120-091 Miltenyi Biotec, Inc.
CD146 FITC ME-9F1 130-102-230 Miltenyi Biotec, Inc.
SCa-1 PE D7 130-102-832 Miltenyi Biotec, Inc.
CD45 FITC 30F11.1 130-110-658 Miltenyi Biotec, Inc.
CD140b PE APB5 130-118-457 Miltenyi Biotec, Inc.
CD, cluster of differentiation; PE, phycoethrin; FITC, fluorescein isothiocyanate.
Figure 1. XTT assays of BM-MSCs and PB-MSCs to measure the prolif-
eration rate. Both MSCs were seeded at 125, 250, 500 and 1,000 cells/well 
and allowed to grow for 7 days then the optical density was measured. The 
proliferation rate of BM-MSCs was higher than that of PB-MSCs and it was 
directly proportional to the number of inoculated cells. *P<0.05 vs. PB-MSCs. 
BM-MSCs, bone marrow-mesenchymal stromal cells; PB, peripheral blood; 
OD, optical density.
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PB-MSCs are promising for autologous regenerative 
therapy. Blood samples taken from healthy children could be 
a source of stem cell banks for both autologous and off-shelf 
allogeneic therapy.
Figure 2. Flow cytometric analysis of BM-MSCs and PB-MSCs. BM-MSCs were positive CD29 and negative for other markers, while PB-MSCs were positive 
for CD146, CD29, and CD140b and negative for Sca-1, CD44, CD45, CD90 and CD105. CD, cluster of differentiation; BM-MSCs, bone marrow-mesenchymal 
stromal cells; PB, peripheral blood; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
Figure 3. Differentiation capability of BM-MSCs and PB-MSCs. Osteogenic 
differentiation of (A) BM-MSCs and (B) PB-MSCs. Both stained with Alizarin 
Red (magnification, x10). Adipogenic differentiation of (C) BM‑MSCs and 
(D) PB‑MSCs stained with Oil red O (magnification, x10). Chondrogenic 
differentiation of (E) BM-MSCs and (F) PB-MSCs stained with toluidine 
blue (magnification, x4). BM‑MSCs, bone marrow‑mesenchymal stem cells; 
PB, peripheral blood.
Figure 4. Quantitative analysis of the differentiation capability of BM-MSCs 
and PB-MSCs. (A) Osteogenesis detection by Ca-ion assays. (B) The adipo-
genesis percentage in PB-MSCs and BM-MSCs. (C) Chondro detection by 
GAG assay. Data are shown as the mean ± standard deviation (n=3). *P<0.05 
vs. the control, †P<0.05 vs. BM-MSCs, ‡P<0.05 vs. PB-MSCs. BM-MSCs, 
bone marrow-mesenchymal stromal cells; PB, peripheral blood; chondro, 
chondrogenesis.
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In conclusion, PB-MSCs are easily obtained from the PB 
of young mice. Although PB-MSCs and BM-MSCs have some 
differences in differentiation and surface markers, they have 
very similar biological characteristics. Mouse PB-MSCs are 
a good source of MSCs and a parallel study of PB-MSCs and 
BM-MSCs in mice can shed more light on their biology in 
relation to ageing.
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